Exelixis Profile

Exelixis Patent Grants

Process for preparing quinoline derivatives

Patent Number 9365516 - June 14, 2016

A process for preparing a compound of Formula I is disclosed: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl…

Inhibitors of PI3K-delta and methods of their use and manufacture

Patent Number 9346807 - May 24, 2016

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making…

Combinations of kinase inhibitors for the treatment of cancer

Patent Number 9011863 - April 21, 2015

The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically…

Imidazole based LXR modulators

Patent Number 9000022 - April 7, 2015

Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts…

Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors

Patent Number 8901137 - December 2, 2014

The invention provides compounds of Formula I: that inhibit the PI3Ks and mTOR that are useful in the treatment of cancer in humans when…

Exelixis Patent Applications

LXR MODULATORS

Application Number 20160304499 - October 20, 2016

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X…

LXR MODULATORS

Application Number 20160289222 - October 6, 2016

The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators…

LXR MODULATORS

Application Number 20160280661 - September 29, 2016

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of…

Cabozantinib Dosage Form and Use in the Treatment of Cancer

Application Number 20160022662 - January 28, 2016

This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.

LXR MODULATORS

Application Number 20150299136 - October 22, 2015

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of…

Exelixis Federal Litigation Filings

Exelixis, Inc. v. Kappos

Virginia Eastern District Court - November 9, 2012

Exelixis, Inc. v. Honorable David J. Kappos There are opinions or orders for this case

Virginia Eastern District Court - May 29, 2012

Exelixis, Inc. v. Kappos There are opinions or orders for this case

Virginia Eastern District Court - January 27, 2012

EXELIXIS, INC. v. KAPPOS

District Of Columbia District Court - October 22, 2010

Exelixis Federal District Court Decisions

Exelixis, Inc. v. Honorable David J. Kappos

Virginia Eastern District Court - January 28, 2013

MEMORANDUM OPINION in re 16 Motion for Summary Judgment and 13 Motion for Summary Judgment. Signed by District Judge Leonie M. Brinkema…